Skip to main content
. 2009 Aug 28;11(4):208. doi: 10.1186/bcr2237

Table 4.

Agents targeting the EGFR family under investigation or approved for metastatic breast cancer

Agent Class of agent Target Stage of development in breast cancer
Trastuzumab Monoclonal antibody HER2 Approved
Lapatinib TKI EGFR, HER2 Approved
Erlotinib TKI EGFR II
Cetuximab Monoclonal antibody EGFR II
Gefitinib TKI EGFR Discontinued

EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor.